TAMOXIFEN IN HORMONE DEPENDENT BREAST CANCER Cecilia Gallego Irene Gallego Ignacio Gallego Beatriz Galván Yanira García Rafael García Rubén García Alberto.

Slides:



Advertisements
Similar presentations
Progress Against Breast Cancer
Advertisements

© 2013 North American Menopause Society. Menopause. 2013;20(9): Key points from the 2013 Position Statement of The North American Menopause Society.
Breast Cancer Systemic Therapy for Early Stage Disease
Oncology The study of cancer. What is cancer? Any malignant growth or tumor caused by abnormal and uncontrolled cell division May be a tumor but it doesn’t.
Pharmacogenetics and the Management of Breast Cancer: Optimization of Tamoxifen Therapy Mark E. Sobel, M.D., Ph.D. Executive Officer American Society for.
Breast Cancer and Hormone Therapy Student: Lisa Kiesow Faculty: Dr. Nancy Bachman Abstract Breast cancer is the most commonly occurring cancer in women.
Systemic therapy for Metastatic Breast Cancer Jo Anne Zujewski, MD National Cancer Institute May 2011.
Ibrance® - Palbociclib
PCR Application: Can Breast Cancer be Cured?. Normal, Healthy Cells Cells can change or differentiate to become specialised according to the tissue that.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Hormones & Hormone Antagonists Chapter 40 - Katzung
Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture By: Reem Sallam, MD, MSc, PhD.
Tamoxifen Pharmacogenetics and Prediction of Breast Cancer Relapse After Administration of Tamoxifen Matthew P. Goetz, MD Assistant Professor of Oncology.
Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.
BREAST CANCER GROUP 6 :  Nuraini Ikqtiarzune Haryono( )  Tri Wahyu Ningsih ( )  Rani Yuswandaru ( )  Anita Rheza Fitriana Putri( )
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
Pharmacogenetics of Tamoxifen An FDA Perspective
Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug metabolite ratios in blood Levo et al. Forensic Science International.
Outcome According to CYP2D6 Genotype Among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial.
 General recommendations -adjuvant systemic therapy :with tamoxifen or multiple-chemotherapy agent :lower the incidence of recurrence by about 30% - in.
Breast Cancer By: Christen Scott.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Principles of Hormonal Therapy Justus Apffelstaedt University of Stellenbosch These Power Point presentations are free to download only for academic purposes,
Pharmacogenetics & Pharmacogenomics Personalized Medicine.
Istituto Nazionale per la Ricerca sul Cancro Genoa – Italy
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Tamoxifen, Endoxifen, and CYP2D6 Sally Usdin Yasuda, MS, PharmD Senior Reviewer, Division of Clinical Pharmacology 1 Office of Clinical Pharmacology Center.
Food and Drug Administration Regulatory Implications of The WHI Study Eric Colman, MD Center for Drug Evaluation and Research Division of Metabolic and.
Aubert RE et al. ASCO 2009; Abstract CRA508. (Oral Presentation)
Breast Cancer Prevention Art or Science? Kristi McIntyre M.D. Texas Oncology 2005.
A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study Robertson.
Cancer, Exercise & Bone Health
Menopausal Hormone Replacement Professor Gordana Prelevic, MD, DSc, FRCP Consultant Endocrinologist Royal Free Hampstead NHS Trust Whittington Health.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
They deserve personalized treatment Your patients are unique.
Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects Linas Martinaitis Erasmus =)
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
ESMO 2011 Breast Cancer BOLERO-2 Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October 12, 2011.
Genes, Populations, and the Environment Biology Basics 3.
A RAY OF HOPE: TAMOXIFEN POWERPOINT PRESENTATION BY NEIL RAKHOLIA
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Joanne Edwards Medical Information Manager ASCO Tech Assessment Update Commercial Implications & Promotional Guidance.
Cancer Therapies DNA microarrays are used to assess the relative expression of thousands of genes simultaneously—relative expression means that.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
Treatment Options for Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Ongoing Studies This program is supported by an educational.
Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,
Breast Cancer Mechanisms 1. 2 Her
Treatment for Cancer. Surgery Treatment and prognosis depend on severity and spread of the cancer Treatment and prognosis depend on severity and spread.
University of Auckland Nursing 785 Assignment 3. Marc McLaughlin
NUR 210: Women’s Health Agents Pharmacology: Wanda Lovitz, APRN.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
HORMONE REPLACEMENT THERAPY (HRT) Evidence-based Guidelines Dr Mahdy El- Mazzahy Damietta general Hospital 7 th International Annual Congress “Alexandria”
ABIRA KHAN TUMOR MARKERS & CANCER TREATMENT. TUMOR MARKERS Biological substances synthesized and released by cancer cells or produced by the host in response.
Anticancer drugs: chemotherapy. Hormonal treatment  Hormone-receptor positive (hormone dependent) forms of breast, prostate and ovarian cancer are subject.
Screening for Ovarian Cancer
AROMATASE INHIBITORS.
2010 ASCO Breast Cancer Symposium Abstract 221
hormones and hormonal antagonists
Aromatase Inhibitors. Aromatase Inhibitors.
JOURNAL OF CLINICAL ONCOLOGY 25:
Breast Health Katherine B. Lee, MD, FACP April 26, 2018.
Chapter 61 Estrogens and Progestins: Basic Pharmacology and Noncontraceptive Applications 1.
Bergh J et al. SABCS 2009;Abstract 23.
Treatment of HR+ Breast Cancer: A Clinical Update
Simona Borštnar, MD, PhD Division of Medical Oncology
ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.
ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES
DISSECTING THE DECISION
Fertility Preservation in Breast Cancer
Presentation transcript:

TAMOXIFEN IN HORMONE DEPENDENT BREAST CANCER Cecilia Gallego Irene Gallego Ignacio Gallego Beatriz Galván Yanira García Rafael García Rubén García Alberto García

PHARMACOGENETICS OF TAMOXIFEN

BREAST CANCER Is the most common cancer in women. Is the most common cancer in women. RISK FACTORS: - Family history - Nulliparity - Early menarche - Elderly - Personal history of breast cancer RISK FACTORS: - Family history - Nulliparity - Early menarche - Elderly - Personal history of breast cancer IMPACT IN SPAIN: IMPACT IN SPAIN: - 36 new cases per inhabitants/year. - 12% of women will suffer from breast cancer % will die from cancer.

TAMOXIFEN Selective estrogen receptor Selective estrogen receptor It acts as anti-estrogens in breast tissue and partial agonist in some organs. It acts as anti-estrogens in breast tissue and partial agonist in some organs. Dose: 20 mg/day for 5 years. Dose: 20 mg/day for 5 years. Beneficial effects on lipid metabolism and bone. Beneficial effects on lipid metabolism and bone. TREATMENT OF HORMONO-DEPENDENT BREAST CANCER

PHARMACOGENETIC AND METABOLISM

PHARMACOGENETIC

MODULATION OF THERAPY ESR1, ESR2 Genes estrogen receptor ESR1, ESR2 Genes estrogen receptor Loos of exon 5 ERd5 Mutated receptor no recognized by tamoxifen ERd5 Mutated receptor no recognized by tamoxifen CYCLIN D1 Activation of the expression of estrogen receptors CYCLIN D1 Activation of the expression of estrogen receptors CYP17A1 Increase the levels of circulating estrogens CYP17A1 Increase the levels of circulating estrogens

CYP2D6 Cr. 22, CYP 450,family 2, subfamily D Cr. 22, CYP 450,family 2, subfamily D No related to the metabolism of precarcinogenesis No related to the metabolism of precarcinogenesis Polymorphism do no show interindividual differences in the probability of developing cancer Polymorphism do no show interindividual differences in the probability of developing cancer Mutant alleles Gene polymorphisms Enzyme activity increased, decreased or void Mutant alleles Gene polymorphisms Enzyme activity increased, decreased or void PHARMACOGENETIC TEST  Amplichip CYP450-Roche: PCR amplification Reports to genotype and metabolizer phenotype of the patient  Technique of Single Base Extension: specific oligonucleotides and amplified PCR Detected a small number of mutations in each region

NORMAL ALLELES CYP2D6*1 Enzyme with catalytic activity MUTANT ALLELES CYP2D6*2, *33,*35 Enzyme with catalytic activity CYP2D6*4, *5 Reduced metabolic activity CYP2D6*3, *4, *5, *6 Nonfunctional enzyme activity (white people) CYP2D6 amplified Enzyme activity increased

TAMOXIFEN AND GENETIC STUDY????? A gene test could predict the efectiveness of Tamoxifen A gene test could predict the efectiveness of Tamoxifen searching changes in CYP2D6 genes searching changes in CYP2D6 genes The study be held because the metabolism of Tamoxifen shows a great variability: The study be held because the metabolism of Tamoxifen shows a great variability: - FAST METABOLICERS: 60% - INTERMEDIATE METABOLICERS: 33% - SLOW METABOLICERS: 7% The utility could prevent: The utility could prevent: - Therapeutic failure - Toxicity - Impredecible interactions

Inheritance of genetic variants Increased risk of recurrence: Inheritance of genetic variants Increased risk of recurrence: - FAST METABOLICERS: 14,9% - INTERMEDIATE METABOLICERS: 20,9% - SLOW METABOLICERS: 29%  ONLY RECOMMENDED IN PATIENTS WITH A RELEVANT PHARMACOLOGICAL HISTORY  Treatment failure is also due to the influence of enviromental factors not detected in the genetic test.  Genetic mutations in the 2 alleles (homozygous) Recurrence time and Survival Recurrence time and Survival affecting only 7% of the population affecting only 7% of the population

CURRENT USES OF TAMOXIFEN Adjuvant treatment after surgery. Adjuvant treatment after surgery. Neoadjuvant treatment before surgery. Neoadjuvant treatment before surgery. Advanced stages of the disease palliative. Advanced stages of the disease palliative. Prevention of breast cancer in women at high risk. Prevention of breast cancer in women at high risk.  In pre- and postmenopausal women.

OTHER ALTERNATIVE DRUGS (I) Anti-estrogenic of SECOND GENERATION A. Nonsteroidal: Raloxifen. Similar to tamoxifen. Similar to tamoxifen. B. Steroidal: Pure antiestrogen (ICI). Reduce side effects of tamoxifen and improve efficiency. Reduce side effects of tamoxifen and improve efficiency. Experience shorter. Experience shorter. Second choice. Second choice.

OTHER ALTERNATIVE DRUGS (II) AROMATASE INHIBITORS o The most used: anastrozole, letrozole, formestane. o Action: adrenal suppression chemical. o Block the synthesis of androgens (-) estrogens. o Postmenopausal.

OTHER ALTERNATIVE DRUGS (III)  More used: megestrol acetate.  Action: - Cell cytotoxic effect. - Anti-estrogenic effect and gonadotropins.  Adjuvant effect. LHRH ANALOGS  More used: goserelin.  Action: chemical suppression.  Adjuvant tamoxifen.  Premenopausal. PROGESTOGENS

BREAST CANCER TREATMENT PREMENOPAUSAL WOMEN TREATMENT OF FIRST CHOICE: TAMOXIFEN TREATMENT OF FIRST CHOICE: TAMOXIFEN - Adjuvants: LHRH analogs or progestogens. TREATMENT OF SECOND ELECTION: RALOXIFEN, FULVESTRANT. TREATMENT OF SECOND ELECTION: RALOXIFEN, FULVESTRANT. TREATMENT OF THIRD ELECTION: AROMATASE INHIBITORS. TREATMENT OF THIRD ELECTION: AROMATASE INHIBITORS. POSTMENOPAUSAL WOMEN TREATMENT OF FIRST CHOICE: TAMOXIFEN. TREATMENT OF FIRST CHOICE: TAMOXIFEN.Adjuvants:Progestogens. TREATMENT OF SECOND ELECTION: AROMATASE INHIBITORS. TREATMENT OF SECOND ELECTION: AROMATASE INHIBITORS.

BREAST CANCER TREATMENT ADJUVANT TREATMENT: Chemotherapy + Tamoxifen. ADJUVANT TREATMENT: Chemotherapy + Tamoxifen. NEOADJUVANT TREATMENT: Chemotherapy + Surgery + Chemotherapy/Radiotherapy + Tamoxifen. NEOADJUVANT TREATMENT: Chemotherapy + Surgery + Chemotherapy/Radiotherapy + Tamoxifen. ADVANCED STAGES: Tamoxifen/Aromatase inhibitors + Polichemotherapy. ADVANCED STAGES: Tamoxifen/Aromatase inhibitors + Polichemotherapy. PREVENTION: Tamoxifen. PREVENTION: Tamoxifen.

DRUG INTERACTIONS OF TAMOXIFEN

CYP3A4 INDUCERS CYP3A4 inducers act by activating the nuclear receptor PXR and stimulate the metabolism of tamoxifen. The association of tamoxifen with these drugs reduces the effectiveness of tamoxifen. CYP3A4 inducers are: Several anticancer drugs: cyclophosphamide, docetaxel, erlotinib, flutamide, ifosfamide and paclitaxel. Several anticancer drugs: cyclophosphamide, docetaxel, erlotinib, flutamide, ifosfamide and paclitaxel. Rifampicin is the most powerful inducer. Rifampicin is the most powerful inducer. Tamoxifen is a weak PXR activator. Tamoxifen is a weak PXR activator.

MITOMYCIN C + TAMOXIFEN This association can provoke an haemolytic uraemic syndrome: - Mitomycin C causes subclinical endotelial damage. - Tamoxifen has got thrombotic effect.

AROMATASE INHIBITORS FIRST GENERATION Does the association with aminoglutethimide improve the response at treatment? - Yes. Plasmatic levels of estrogen decrease. - No. Sensibility of estrogenic receptors of tumor cells increases. - No. Toxicity increases due to administration of two drugs.

AROMATASE INHIBITORS THIRD GENERATION There are relevant pharmacokinetic interactions resulting in decreased plasma concentrations of third generation aromatase inhibitors when combined with tamoxifen. There are relevant pharmacokinetic interactions resulting in decreased plasma concentrations of third generation aromatase inhibitors when combined with tamoxifen. LETROZOLE Combination of tamoxifen and letrozole: The letrozole concentrations approximately 35-40% lower than when letrozole is used alone. ANASTRAZOLE Single agent anastrozole is superior to tamoxifen or the combination of both. In recent clinical studies, anastrozole, letrozole and exemestane have shown advantages over tamoxifen as treatment for advanced disease.

MEDROXYPROGESTERONE What do we use them for? What do we use them for? - Inducing normal menstruation. - Decreasing the risk of developing cancer of the uterus in patients taking estrogens. - Decreasing the risk of developing cancer of the uterus in patients taking estrogens. Medroxyprogesterone treatment in postmenopausal women increases the incidence of breast cancer.

Concomitant use of tamoxifen and medroxyprogesterone increases the liver enzymes. Concomitant use of tamoxifen and medroxyprogesterone increases the liver enzymes. Tamoxifen induces signs of autophagy, which was enhanced when it was combined with MPA. Tamoxifen induces signs of autophagy, which was enhanced when it was combined with MPA.

When we use tamoxifen with HRT may occur: SIDE EFFECT: The beneficial effects of tamoxifen on cardiovascular risk factors (because tamoxifen reduces the cholesterol level in blood) are unchanged in current HRT users, whereas they may be attenuated in women who start HRT while on tamoxifen. SIDE EFFECT: The beneficial effects of tamoxifen on cardiovascular risk factors (because tamoxifen reduces the cholesterol level in blood) are unchanged in current HRT users, whereas they may be attenuated in women who start HRT while on tamoxifen. POSITIVE EFFECT: Increases bone density in bones, mainly in the femur. POSITIVE EFFECT: Increases bone density in bones, mainly in the femur. HORMONE REPLACEMENT THERAPY (HRT)

Drug Interactions in the Treatment of Breast Cancer and Depression

Depression in Breast Cancer The estimated point prevalence of major depressive disorder in all women is in the range of 3.5%–7% The estimated point prevalence of major depressive disorder in all women is in the range of 3.5%–7% In comparison, the rate of depression in women with breast cancer is estimated to be in the range of 10%–25% In comparison, the rate of depression in women with breast cancer is estimated to be in the range of 10%–25%

Endocrine Therapy for Breast Cancer Analyses of thousands of women treated with 5 years of tamoxifen versus no endocrine therapy for invasive breast cancer demonstrate a 31% decrease in annual breast cancer death rate with tamoxifen. Analyses of thousands of women treated with 5 years of tamoxifen versus no endocrine therapy for invasive breast cancer demonstrate a 31% decrease in annual breast cancer death rate with tamoxifen. Tamoxifen is antiestrogenic in the breast, resulting in decreased breast cancer development and recurrence, as well as in the brain, leading to hot flashes as side effect Tamoxifen is antiestrogenic in the breast, resulting in decreased breast cancer development and recurrence, as well as in the brain, leading to hot flashes as side effect

Treatments for Concurrent Hot Flashes and Depression Prospective randomized clinical trials have demonstrated that selective serotonin reuptake inhibitors (SSRIs) decrease vasomotor symptoms in healthy menopausal women and women with breast cancer. Prospective randomized clinical trials have demonstrated that selective serotonin reuptake inhibitors (SSRIs) decrease vasomotor symptoms in healthy menopausal women and women with breast cancer. In general, these studies have shown that most of these medications decrease hot flash frequency by about 60%, compared with a decrease of 25%–35% with placebo. In general, these studies have shown that most of these medications decrease hot flash frequency by about 60%, compared with a decrease of 25%–35% with placebo.

Tamoxifen Metabolism Tamoxifen is converted to endoxifen principally by a noninducible P450 enzyme that is coded for by the most polymorphic, and most studied, gene in the cytochrome P450 system: CYP2D6. Tamoxifen is converted to endoxifen principally by a noninducible P450 enzyme that is coded for by the most polymorphic, and most studied, gene in the cytochrome P450 system: CYP2D6. In one study, breast cancer patients treated with tamoxifen who were homozygous for a poor metabolizer genotype (*4/*4) had significantly lower serum concentrations of endoxifen than those with the active. In one study, breast cancer patients treated with tamoxifen who were homozygous for a poor metabolizer genotype (*4/*4) had significantly lower serum concentrations of endoxifen than those with the active.

Coadministration of Tamoxifen and an SSRI or SNRI In addition to genetic inactivation of CYP2D6, CYP2D6 activity can be decreased by medications that inhibit the enzyme. In addition to genetic inactivation of CYP2D6, CYP2D6 activity can be decreased by medications that inhibit the enzyme. Use of CYP2D6 inhibitors in patients who are being treated with tamoxifen, even if they have the homozygous active genotype, could potentially affect breast cancer outcomes, in a manner similar to the poor metabolizer genotype. Use of CYP2D6 inhibitors in patients who are being treated with tamoxifen, even if they have the homozygous active genotype, could potentially affect breast cancer outcomes, in a manner similar to the poor metabolizer genotype. Inhibition of tamoxifen conversion to endoxifen may decrease the efficacy of tamoxifen therapy and increase the risk of breast cancer development or recurrence. Several SSRIs and SNRIs are potent, moderate, or mild inhibitors of CYP2D6. Inhibition of tamoxifen conversion to endoxifen may decrease the efficacy of tamoxifen therapy and increase the risk of breast cancer development or recurrence. Several SSRIs and SNRIs are potent, moderate, or mild inhibitors of CYP2D6.

An observational study of women treated with tamoxifen demonstrated low serum concentrations of endoxifen in those concomitantly treated with strong inhibitors of CYP2D6, such as paroxetine and fluoxetine, and intermediate levels of endoxifen in those concomitantly treated with weak inhibitors, such as sertraline and citalopram. An observational study of women treated with tamoxifen demonstrated low serum concentrations of endoxifen in those concomitantly treated with strong inhibitors of CYP2D6, such as paroxetine and fluoxetine, and intermediate levels of endoxifen in those concomitantly treated with weak inhibitors, such as sertraline and citalopram. It is noteworthy that venlafaxine, which does not inhibit CYP2D6, had little effect on endoxifen concentration. It is noteworthy that venlafaxine, which does not inhibit CYP2D6, had little effect on endoxifen concentration. Women with decreased CYP2D6 metabolism had increased rates of breast cancer recurrence and decreased relapse-free survival time. Women with decreased CYP2D6 metabolism had increased rates of breast cancer recurrence and decreased relapse-free survival time.

Possible recommendations Routine CYP2D6 genotyping for patients being treated with tamoxifen. Routine CYP2D6 genotyping for patients being treated with tamoxifen. Alternative treatment options (such as citalopram, gabapentin, and venlafaxine) Alternative treatment options (such as citalopram, gabapentin, and venlafaxine) Other therapies. For example, ovarian suppression can be used for treatment of premenopausal women, and aromatase inhibitor therapy can be an excellent option for postmenopausal women. Other therapies. For example, ovarian suppression can be used for treatment of premenopausal women, and aromatase inhibitor therapy can be an excellent option for postmenopausal women.

QUESTIONS

What is the main metabolite of the tamoxifen? What is the main metabolite of the tamoxifen? What is the main citochrome implicated? What is the main citochrome implicated? When would we do a genetic test? When would we do a genetic test? Endoxifen CYP2D6 In patients with a relevant pharmacological history

What is the use of tamoxifen? What is the use of tamoxifen? - Adjuvant treatment after surgery. - Neoadjuvant treatment before surgery. - Advanced stages of the disease palliative. - Prevention of breast cancer in women at high risk.

What SSRI would you use in a woman in treatment with tamoxifen? What SSRI would you use in a woman in treatment with tamoxifen? Venlafaxine

BIBLIOGRAPHY Stockley’s Drug Interactions. Sixth edition. Stockley’s Drug Interactions. Sixth edition. ajp.psychiatryonline.org ajp.psychiatryonline.org jama.ama-assn.org jama.ama-assn.org